secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001213900-24-012649
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics appoints Jeff Cole as COO with $405K salary and equity incentives
--------------------------------------------------------------------------------

- Jeff Cole appointed Chief Operating Officer, newly created role, effective Feb 8, 2024.
- Annual base salary $405K, discretionary bonus up to 40% of base, and 150,000 stock options.
- Cole brings 25+ years exp in pharma operations; previously at Espero BioPharma and Valeant.
- He will oversee manufacturing, supply chain, IP, commercialization, partnering for tecarfarin.
- Appointment comes as Cadrenal advances tecarfarin toward Phase 3 pivotal trial for anticoagulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024012649/0001213900-24-012649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024012649/ea193419-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-012649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer